Apogee files to go public, unveiling IL-13 ambitions and more

Apogee Therapeutics launched last year with $169 million in private financing and is headed for an IPO.

The startup was spun out of Paragon Therapeutics in December but with few details about exactly what targets it would go after. Thursday’s IPO filing provides some details.

Its drug APG777 is an…
Click here to view original post

Advertisement — Advertise with Biotech Networks